The partnership – announced yesterday – will aim to create a range of production platforms that combine G-Con’s line of mobile ‘pod’ cleanrooms with Sartorius’ single-use biomanufacturing technologies.
Maik Jornitz, SSB’s Senior Vice President of Marketing for Bioprocess Solutions, predicted that: “The combined product portfolio will fundamentally change the way biopharmaceutical manufacturing processes will be designed and configured.
He explained that providing SSB’s tech for media preparation, seed fermentation, cell culture, ultra-diafiltration, chromatography and viral clearance techs in G-Con’s modular format will let manufacturers build entire process from individual modules.
This was echoed by G-Con president Barry Holtz, who added that: “Our common goal is to combine our complementary expertise to develop revolutionary solutions for the next generation of flexible, single-use manufacturing concepts.”
The deal – financial terms of which were not disclosed – is SSB’s fourth in the biologics manufacturing space in less than 12 months.
Last May the firm launched a new line of small-scale bioreactors, citing growing industry demand for technologies that to bridge the gap between process development and commercial scale biomanufacturing.
The following month SSB teamed up with German packaging company Sudpack Medica AG in a deal focused on the development of plastic packaging films for bioproduction applications.
More recently SSB partnered with industrial giant GE Healthcare in an agreemkent that granted the French firm access to patents GE has licensed from purification and sensor system developer SciLog covering aseptic transfer and bioprocessing technologies.